CASI Pharmaceuticals Inc. CASIF
0.13
(0.03)
(18.75%)
as of 25 Sep
- Market cap
- $12.4M
- P/E
- 0.0×
Follow CASIF
| Older periods | Jun '25 | Sep '25 | Dec '25 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
830.72% | 669.76% | 271.28% | 0.00% | |
| (113.71%) | (112.12%) | (121.17%) | 0.00% | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
385.20% | 242.48% | 164.33% | 0.00% | |
Average Days of Receivables |
62.02 | 35.47 | 72.11 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | (4.83) | — | |
Free Cash Flow |
— | — | (89.59) | — | |
Capital Expenditures |
— | — | (1.55) | — | |
Piotroski F-Score |
— | — | 0.00 | — | |
| Other line items | |||||
Cash ROIC |
0.00% | 0.00% | 1,071.38% | 0.00% | |
Accounts Receivable Turnover |
4.82 | 3.90 | 2.13 | 0.00 | |
Accounts Payable Turnover |
23.31 | 14.83 | 5.62 | 0.00 | |
Inventory Turnover |
2.07 | 2.22 | 3.11 | 0.00 | |
Average Days of Payables |
15.79 | 11.86 | 36.55 | 0.00 | |
Days of Inventory on Hand |
66.61 | 55.30 | 54.84 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | — | |
Research and Development Expense of Revenue |
28.03% | 32.55% | 30.46% | — | |
Selling, General and Administrative Expense of Revenue |
144.13% | 165.46% | 225.06% | — | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 62.42% | — | |
Interest Coverage |
0.00 | 0.00 | 0.00 | — | |
Operating CF/Net income |
0.00 | 0.00 | 1.83 | — | |
Depreciation/Fixed assets |
0.00 | 0.00 | 1.18 | 0.00 | |
Capex/Depreciation |
— | — | (0.19) | — | |
Revenue per Share |
2.04 | 1.67 | 1.12 | — | |
Operating CF per Share |
0.00 | 0.00 | (4.75) | — | |
Capex per Share |
0.00 | 0.00 | (0.08) | — | |
Capex to Sales |
0.00 | 0.00 | 0.07 | — | |
Net Profit Margin |
(148.56%) | (183.93%) | (232.03%) | — |
Columns are period end dates